{"nctId":"NCT00490971","briefTitle":"A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder","startDateStruct":{"date":"2006-05"},"conditions":["Bipolar Disorder"],"count":768,"armGroups":[{"label":"Paliperidone ER","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone ER"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olanzapine"]}],"interventions":[{"name":"Olanzapine","otherNames":[]},{"name":"Paliperidone ER","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria for Bipolar I Disorder Most Recent Episode Manic or Mixed (with or without psychotic features)\n* have a history of at least 2 previously documented mood episodes associated with Bipolar I Disorder (1 of which must be a manic or mixed episode) that required medical treatment within the past 3 years\n* a total score of at least 20 on the YMRS at screening and at Day 1 of the study.\n\nExclusion Criteria:\n\n* Meet DSM-IV criteria for any type of episode associated with bipolar disorder other than Bipolar I Disorder Most Recent Episode Manic or Mixed\n* Meet DSM-IV criteria for rapid cycling\n* Meet DSM-IV criteria for schizoaffective disorder\n* Known or suspected borderline or antisocial personality disorder\n* be, in the opinion of the investigator, at significant immediate risk for suicidal or violent behavior during the course of the study based on current status or prior history (e.g., suicide attempts during previous episodes).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder","description":"Time to first recurrence of any mood symptoms (ie, manic or depressive) associated with bipolar I disorder during the maintenance phase, after maintaining clinical stability during continued treatment with paliperidone ER over a period of 15 weeks. The time period was from occurrence of acute manic or mixed episode to Week 15. This outcome was measured using combination of various scales, hospitalization for any mood symptoms, use of any medicines for an mood episode and clinical events suggestive of recurrent mood episode associated with bipolar I disorder.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"85.0","spread":null},{"groupId":"OG003","value":"140.0","spread":null},{"groupId":"OG004","value":"541","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"283.0","spread":null},{"groupId":"OG003","value":"558.0","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recurrence of Manic Symptoms Associated With Bipolar I Disorder","description":"This was the key secondary efficacy end-point. Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of manic symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"194.0","spread":null},{"groupId":"OG003","value":"498.0","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"550.0","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recurrence of Depressive Symptoms Associated With Bipolar I Disorder","description":"Pali/Pali and Pali/Placebo were compared with each other with respect to time to recurrence of depressive symptoms. The criterias used for this analysis were similar to criterias used for primary analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"503.0","spread":null},{"groupId":"OG003","value":"448.0","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Young Mania Rating Scale (YMRS): Change From Baseline","description":"This is method by which condition of patient suffering with mania is checked. In this scale patient's condition is assessed using 11 items. A severity rating is assigned to each of 11 items based on the how subject feels of his or her condition and the physicians observation of patients behavior. The range of the scale is 0 to 60. A higher score indicates a more severe condition. Change from baseline (Day 105) in the double-blind maintenance phase to the last postbaseline assessment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.2","spread":"11.23"},{"groupId":"OG001","value":"-19.3","spread":"10.25"},{"groupId":"OG002","value":"9.0","spread":"11.78"},{"groupId":"OG003","value":"4.2","spread":"9.33"},{"groupId":"OG004","value":"1.3","spread":"6.26"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Montgomery-Asberg Depression Rating Scale (MADRS)","description":"The MADRS consists of 10 items covering all the important complaints which patient with depression have (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Item is scored from 0 (normal) to 6 (severe). Total score (0 to 60) is calculated by adding the scores of all 10 items. A higher score represents a more severe condition. Negative Change in Score Indicates Improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"8.21"},{"groupId":"OG001","value":"-2.7","spread":"7.82"},{"groupId":"OG002","value":"6.0","spread":"9.16"},{"groupId":"OG003","value":"6.1","spread":"10.10"},{"groupId":"OG004","value":"2.5","spread":"7.10"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Global Assessment of Functioning (GAF): Change From Baseline","description":"This scale is used when the clinical progress of a subject needs to be assessed in global terms, using a single measure. The GAF scale is rated with respect to psychological, social, and occupational functioning at the time of the assessment only. A higher score indicates a better functioning, with an overall range from 1 to 100. Positive Change in Score Indicates Improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"17.38"},{"groupId":"OG001","value":"20.8","spread":"18.26"},{"groupId":"OG002","value":"-15.2","spread":"20.93"},{"groupId":"OG003","value":"-8.9","spread":"17.75"},{"groupId":"OG004","value":"-4.2","spread":"13.98"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Clinical Global Impression - Bipolar Disorder - Severity of Illness (CGI-BP-S): Change From Baseline","description":"The CGI-BP-S rating scale is used to rate the severity of bipolar disorder, including both depressed and manic components, on a 7-point scale ranging from 1 (not ill) to 7 (very severely ill). This scale permits a global evaluation of the subject's bipolar condition at a given time. Negative Change in Score Indicates Improvement.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"-3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":614},"commonTop":["Insomnia","Headache","Somnolence","Weight increased","Akathisia"]}}}